Ali K. Abu-Alfa

Associate Professor of Medicine
Director of Clinical Trials
Director, Peritoneal Dialysis Program
Associate Medical Director for Outpatient Dialysis
Section of Nephrology

My primary clinical interests are Peritoneal Dialysis, Nephrogenic Systemic Fibrosis (NSF), cancer-related renal disease and Chronic Kidney Disease/dialysis and associated complications, namely anemia and mineral and bone disorders (CKD-MBD).

My primary research interests relate to the delivery and methods of peritoneal dialysis as well as patient choice in renal replacement therapy. I am also actively involved in the issues surrounding Nephrogenic Systemic Fibrosis and Gadolinium Containing Contrast Agents, focusing on epidemiology, mechanism of disease, policy and risk reduction. Finally, I am involved in efforts aiming at optimizing the care of patients with chronic kidney disease with particular focus on anemia management and treatment of secondary hyperparathyroidism. An emphasis is placed on the maximal utilization of informatics in the design and implementation of projects.

PubMed Search for articles by faculty member

Selected Recent Publications

• Abu-Alfa , AK : The Impact of NSF on the Care of Patients with Kidney Disease. Proceedings of the First Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium Based MR Contrast Agents. J Am Coll Radiol 2008; 5: 45-52.
• Saab G and Abu-Alfa, AK: Nephrogenic systemic fibrosis-Implications for nephrologists. Eur J Radiol. 2008 May; 66(2):208-12.
• Abu-Alfa, AK , Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D and Audhya P. Darbepoetin alfa The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2008 Apr; 24(4):1091-100.
• Kuo, PH, Kanal, M, Abu-Alfa, AK and Cowper, SE: Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis. Radiology 2007, 242(3):647-9.
• Saab G and Abu-Alfa, AK: Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology 2007; 244: 930.
• Saab G and Abu-Alfa, AK: Will Dialysis Prevent the Development of Nephrogenic Systemic Fibrosis After Gadolinium-Based Contrast Administration? AJR Am J Roentgenol. 2007 Sep; 189 (3): W169.
• Finkelstein F, Healy H, Abu-Alfa, AK, Ahmad A, Brown F, Gehr T, Nash K, Sorkin M and Mujais S, on behalf of the Icodextrin High Transporter Trial Group. Superiority of Icodextrin Compared to 4.25% Dextrose for Peritoneal Ultrafiltration. J Am Soc Nephrol 2005, 16: 546-554.

Education:	B.S., 1985: American University of Beirut M.D., 1985: American University of Beirut
Training:	Residency: Northwestern University Fellowship: Yale University

Contact

Campus Address
Section of Nephrology
Department of
Internal Medicine
Yale School of Medicine
P.O. Box 208029
New Haven, CT
06520–8029

E-mail
ali.abu–alfa@yale.edu